Krill Oil.

Astaxanthin is a fat-soluble carotenoid that krill oil naturally contains, and it partitions into the oil where it helps shield the fragile EPA and DHA double bonds from oxidation. Because astaxanthin needs dietary fat for uptake, the oil also acts as the lipid vehicle that carries it across the gut, so the two support each other in both directions.

Vitamin E is the main fat-phase chain-breaking antioxidant that interrupts lipid peroxidation, so it helps keep the long-chain omega-3s in krill oil from oxidizing both on the shelf and in the body. Taking in more of these readily oxidized fats also raises the body's use of vitamin E, which is the settled reason the two are routinely paired.

Coenzyme Q10 is highly fat-loving and poorly absorbed on its own, since its uptake depends on dietary fat to stimulate bile flow and form the micelles that ferry it across the gut. Taken alongside krill oil, the oil supplies that lipid matrix and supports how much CoQ10 reaches circulation.

Most krill oil EPA and DHA is bound in phosphatidylcholine, so every dose delivers choline as part of the molecule. Total choline intake from a formula has to count the krill phospholipid fraction.

Krill oil is largely phosphatidylcholine with long-chain omega-3 fatty acids at the sn-2 position, so added phosphatidylcholine feeds the same membrane phospholipid pool. The phospholipid form also self-emulsifies, so absorption does not depend on a fatty meal.

Cholecalciferol needs a lipid phase and bile-driven micelle formation to be absorbed, and krill phospholipids act as both lipid and emulsifier. Co-dosing raises the absorbed fraction relative to a dry tablet taken alone.

MK-7 is a long-chain fat-soluble quinone that travels in chylomicrons, so uptake improves in the presence of a lipid carrier such as krill phospholipid. This is an absorption effect, not a change in either nutrient's own action.

Long-chain omega-3 fatty acids have many double bonds and oxidise readily, and the tocopherol that intercepts that chain reaction is regenerated by ascorbate at the membrane surface. Vitamin C keeps the protective tocopherol pool working rather than acting on the fatty acids directly.

DHA is the dominant fatty acid of photoreceptor membranes while lutein concentrates in the macular pigment layer, and lutein is carried more efficiently when taken with a phospholipid meal.

Zeaxanthin is a lipophilic xanthophyll whose absorption depends on being incorporated into micelles, which krill phospholipids assist. It then deposits in the same DHA-rich retinal membranes.

Krill oil and fish oil deliver the same two long-chain omega-3 fatty acids in different chemical carriers, phospholipid versus triglyceride or ethyl ester. Running both in one formula stacks the same EPA and DHA total, so the doses have to be read together.

EPA is converted to thromboxane A3, a weaker platelet activator than the arachidonic acid product, while ginkgolides antagonise platelet activating factor. Both nudge normal clotting in the same direction, so the effect is additive when they share a formula.

Garlic organosulfur compounds reduce platelet aggregation through thromboxane-independent routes, adding to the shift that long-chain omega-3 fatty acids produce in eicosanoid balance.

Gingerols inhibit thromboxane synthase, and omega-3 fatty acids shift the eicosanoid substrate pool away from arachidonic acid. The two act at neighbouring points in the same pathway, so effects on normal clotting add.

Salicin metabolites inhibit cyclooxygenase in platelets while omega-3 fatty acids change which fatty acid that enzyme sees. Combining them compounds the shift in normal clotting behaviour.

Eicosapentaenoic acid is one of the two long-chain omega-3s krill oil delivers, carried largely on phospholipids rather than triglycerides. Once incorporated into membranes it competes with arachidonic acid for cyclooxygenase and lipoxygenase, shifting eicosanoid output. Adding separate EPA raises the same pool krill oil is already feeding.

Docosahexaenoic acid concentrates in neural and retinal membrane phospholipids, where it shapes membrane fluidity and receptor behaviour. Krill oil delivers DHA already esterified to phosphatidylcholine, the same chemical arrangement found in those membranes. A separate DHA product adds to the same pool from a triglyceride starting point.

Phospholipid-bound fatty acids are released mainly by pancreatic phospholipase A2 rather than by the lipase that handles triglycerides. Digestive enzyme blends that include phospholipase are therefore acting on the specific bond krill oil presents. This is mechanism, not a measured combination trial.

Bile salts emulsify dietary lipid so that lipase and phospholipase can act at the oil-water interface. Krill phospholipids are amphipathic and self-emulsify to a degree that triglyceride oils do not, so they are less dependent on bile than a standard fish oil. Anyone with reduced bile flow is the group for whom this distinction matters most.

A randomised study tested a cardioprotective diet with and without phytosterol and krill oil supplementation in adults with an inherited pattern of elevated blood cholesterol. Phytosterols compete with cholesterol for micellar space in the gut while omega-3s act on hepatic triglyceride output, so the two work at different steps. Blood lipid levels are markers, not clinical outcomes.

A network meta-analysis compared nutritional supplements studied for joint comfort and mobility, placing krill oil alongside glucosamine among the compared agents. Glucosamine supplies substrate for glycosaminoglycan synthesis while omega-3 phospholipids act on eicosanoid balance in the joint. The comparison was between agents, not a test of the two given together.

Chondroitin is a structural glycosaminoglycan of cartilage matrix and is almost always formulated with glucosamine. Krill oil enters the same category from the lipid mediator side. No trial of the specific combination was identified in this candidate set.

MSM is a small sulfur donor studied for joint comfort during activity, and it appears in the same product category as krill oil. Their mechanisms do not overlap, which is the usual argument for combining them. Combination evidence was not identified here.

Boswellic acids act on 5-lipoxygenase, one of the two enzymes that long-chain omega-3s also compete for as substrate. Acting on the same enzyme from two directions is the reason the pair is co-formulated. Human data on the combination was not identified.

Curcumin and long-chain omega-3s both reduce platelet aggregation in laboratory measures, by different routes. Stacked, those effects add. This is worth flagging for anyone on anticoagulant or antiplatelet medication or approaching surgery, and is a conversation for a clinician rather than a formulation decision.

Nattokinase has fibrinolytic activity in laboratory assays and krill oil's omega-3s reduce platelet aggregation. The two act on different points of clot formation and their directions add. Anyone taking blood-thinning medication should have this pairing reviewed before combining them.

Vitamin K1 is the cofactor for gamma-carboxylation of clotting factors, so it pushes coagulation in the opposite direction to the antiplatelet effect of long-chain omega-3s. The two do not cancel each other out; they act on different arms of haemostasis. Consistency of vitamin K intake matters most for people on vitamin K antagonist medication.

Glutathione peroxidase is a selenoenzyme that reduces lipid hydroperoxides, the products formed when polyunsaturated fatty acids oxidise. Loading membranes with highly unsaturated fatty acids raises the substrate load on that system. This is established biochemistry rather than a combination trial result.

Dihydrolipoic acid regenerates other antioxidants including tocopherol and ascorbate, which is the system that protects membrane polyunsaturated fatty acids from peroxidation. Krill oil raises membrane unsaturation. The connection is redox chemistry, not measured joint or muscle data.

A randomised trial in older adults measured skeletal muscle function and size during krill oil supplementation, and protein intake is the other established input to those endpoints. Omega-3 incorporation into muscle membranes and amino acid availability are different levers on the same outcome. No trial of the two combined was identified here.

Leucine triggers mTORC1-driven muscle protein synthesis while long-chain omega-3s have been reported to sensitise that response. Krill oil's muscle literature is small and mostly in older adults. The pairing is mechanistically reasonable and not yet tested as a combination.

Carnitine carries long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, and long-chain omega-3s are among the fatty acids handled that way. The pairing follows from the transport chemistry. It has not been tested as a combination in the papers identified here.

Collagen peptides supply glycine, proline and hydroxyproline for connective tissue matrix while krill oil acts on the lipid mediator side of joint comfort during activity. They appear together in joint and mobility formulas. Combination evidence was not identified in this candidate set.